MGE Energy, Inc. (MGEE): A Bull Case Theory
We came across a bullish thesis on MGE Energy, Inc. (MGEE) on Value Investing Subreddit Page by TickernomicsOfficial. In this article, we will summarize the bulls' thesis on MGEE. MGE Energy, Inc. (MGEE)'s share was trading at $89.71 as of May 14th. MGEE's trailing P/E was 25.34 according to Yahoo Finance.
A utility employee connecting wires at a power station in order to distribute electricity to customers.
MGE Energy (MGEE), a regulated utility based in Wisconsin, distinguishes itself through financial strength, disciplined capital allocation, and a resilient business model that contrasts sharply with industry peers often burdened by high debt, inflation-driven negative free cash flow, and regulatory pricing constraints. MGEE delivers essential electricity and natural gas services through deeply entrenched infrastructure, creating a durable economic moat supported by a stable, localized customer base and Wisconsin's solid economic environment.
Its real asset-heavy profile gains further appeal in a weakening dollar environment, where the relative value of infrastructure increases and the inflation-adjusted cost of debt becomes more favorable. Unlike many utilities chasing ESG initiatives that fail to produce consistent returns, MGEE has remained focused on fundamentals, avoiding overreach while continuing to generate steady positive free cash flow—a rare achievement in the capital-intensive utility space. The company's strong balance sheet, reasonable leverage, and reliable dividend stream reinforce its role as a stabilizing force in any portfolio, particularly during periods of macroeconomic uncertainty or market volatility.
Insider buying activity adds further credibility to the long-term value proposition, signaling confidence from those closest to the business. MGEE's low-risk core operations, coupled with prudent management and high-quality tangible assets, make it uniquely positioned to deliver both defensive protection and solid long-term returns. In a sector known for slow growth and operational drag, MGEE stands out as a utility that not only preserves capital but also offers compelling upside potential through its stable fundamentals and consistent performance.
MGE Energy, Inc. (MGEE) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 15 hedge fund portfolios held MGEE at the end of the fourth quarter which was 11 in the previous quarter. While we acknowledge the risk and potential of MGEE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MGEE but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
RCI Announces Acquisition of Platinum Plus Gentlemen's Club in Allentown, PA
HOUSTON, June 16, 2025--(BUSINESS WIRE)--RCI Hospitality Holdings, Inc. (Nasdaq: RICK) today announced closing on the acquisition of the upscale Platinum Plus Gentlemen's Club in Allentown, PA, minutes away by car from the airport in Allentown and the casino in Bethlehem. The purchase price totaled $2.0 million, consisting of $1.5 million cash and $0.5 million seller financing at 7% for the club. The purchase price is in line with RCI's acquisition valuation target of 3-5x annualized adjusted EBITDA for a club. Separately, a long-term lease was signed for the property. Eric Langan, President and CEO of RCI Hospitality Holdings, Inc., commented: "This is the sister club to the recently announced acquisition of Platinum West in South Carolina and the third club purchase since the recent launch of our 5-Year 'Back to Basics' Capital Allocation Plan." "Platinum Plus is a well-established business with a seasoned management team. The club adds to our six other locations in the Northeast states and should benefit from our marketing, purchasing and systems know-how." Mr. Langan added that executive management of the two Platinum clubs will stay on to ensure a smooth transition and look for new club acquisitions. The 15,000 square foot Platinum Plus is located at 1251 Airport Road, Allentown, PA 18109. The club is open Monday through Saturday from 11:00 a.m. to 2:00 a.m. and Sunday from 4:00 p.m. to 2:00 a.m. Visit About RCI Hospitality Holdings, Inc. (Nasdaq: RICK) (X: @RCIHHinc) With more than 60 locations, RCI Hospitality Holdings, Inc., through its subsidiaries, is the country's leading company in adult nightclubs and sports bars-restaurants. See all our brands at Forward-Looking Statements This press release may contain forward-looking statements that involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from those indicated, including, but not limited to, the risks and uncertainties associated with (i) operating and managing an adult entertainment or restaurant business, (ii) the business climates in cities where it operates, (iii) the success or lack thereof in launching and building the Company's businesses, (iv) cyber security, (v) conditions relevant to real estate transactions, and (vi) numerous other factors such as laws governing the operation of adult entertainment or restaurant businesses, competition and dependence on key personnel. For more detailed discussion of such factors and certain risks and uncertainties, see RCI's annual report on Form 10-K for the year ended September 30, 2024, as well as its other filings with the U.S. Securities and Exchange Commission. The Company has no obligation to update or revise the forward-looking statements to reflect the occurrence of future events or circumstances. View source version on Contacts Media & Investor Contacts Gary Fishman and Michael Wichman at 212-883-0655 or gfishman@ and mwichman@
Business Wire
23 minutes ago
- Business Wire
Travelers Announces the Start of the 2025 Travelers Championship
HARTFORD, Conn.--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced the start of the 2025 Travelers Championship at TPC River Highlands in Cromwell, Connecticut, the final Signature Event of the PGA TOUR season. This year's tournament marks Travelers' 19th consecutive year as title sponsor, making the company the longest-running title sponsor in the event's history. The 2025 Travelers Championship features the top 10 players in the Official World Golf Ranking, and 45 of the top 50. Players include Scottie Scheffler, the No. 1 player in the world and the tournament's defending champion; Rory McIlroy (No. 2); Xander Schauffele (No. 3); Collin Morikawa (No. 4); and Justin Thomas (No. 5). 'When Travelers first became the title sponsor in 2007, our goal was to make a difference in our community,' said Alan Schnitzer, Chairman and Chief Executive Officer of Travelers. 'We are proud to have done that 19 years running, including three years with an elevated status. After all this time, the Travelers Championship is still a labor of love, made possible with the PGA TOUR's support, the best players in golf, corporate sponsors, community partners, the countless Travelers employees who volunteer their time and, most importantly, the fans. We are looking forward to another great week of golf that will benefit charities throughout the region and generate important economic activity.' Since Travelers became title sponsor in 2007, the tournament has generated tens of millions of dollars for hundreds of local and regional charities. In 2024, 206 nonprofit organizations benefited from the more than $3.2 million generated by the event. This year's primary beneficiary will again be The Hole in the Wall Gang Camp, an organization based in Ashford, Connecticut, that provides a traditional summer camp experience for children with serious illnesses. A variety of other charities – focusing on arts and culture, education, health care, housing, human services, mental health, food insecurity, science and technology, and youth development – also benefit from their involvement with the Travelers Championship. 'The longest-running title sponsor in tournament history is not a milestone we take for granted,' said Andy Bessette, Executive Vice President and Chief Administrative Officer at Travelers. 'We are proud to have played a lead role in building this tournament into one of the few Signature Events on the PGA TOUR, and we are grateful to the countless people – Tournament Director Nathan Grube and his staff, our team at Travelers and so many others – who make this event a success year after year. I can't wait to see how the competition unfolds.' All 72 players in this year's tournament will compete for four rounds, beginning on Thursday, June 19. The Travelers Championship offers a $20 million purse, with $3.6 million going to the winner. Ticketed spectators will be allowed on-site starting Wednesday, June 18. Tournament-related special events are scheduled throughout the week and include The Umbrella at 15 ½ Challenge on Tuesday, where PGA TOUR players compete in a closest-to-the-pin contest at the 40-foot-wide floating green in the shape of the Travelers red umbrella logo. The winner will earn $10,000 from Travelers for the charity of his choice. The Signature Women's Day Breakfast will be held at TPC River Highlands on Thursday, with Hoda Kotb, award-winning journalist, author and CEO, as the keynote speaker. Golf Channel will provide live tournament coverage from 3 to 6 p.m. ET Thursday and Friday, and Saturday and Sunday from 1 to 3 p.m. ET. CBS will provide coverage from 3 to 6:30 p.m. ET Saturday and 3 to 6 p.m. ET Sunday. PGA TOUR Live on ESPN+ will offer live access to marquee and featured groups, as well as certain holes, Thursday through Sunday. The event can also be streamed on Paramount+. For more information about the Travelers Championship, visit Fans can also follow the tournament's social media channels on X, Facebook, Instagram, LinkedIn and TikTok for news and information. About Travelers
Yahoo
28 minutes ago
- Yahoo
AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
MILAN, June 16, 2025 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, presented promising four-year clinical outcomes from 48 relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) patients treated with C-CAR039 (also known as Prizloncabtagene Autoleucel) in greater China, at the European Hematology Association (EHA) 2025 Congress. The study evaluated the safety and efficacy of C-CAR039, a novel anti-CD19/CD20 bi-specific CAR-T therapy. The dual-targeting approach to both CD20 and CD19 antigens aims to enhance therapeutic efficacy and reduce the likelihood of antigen escape, a common mechanism of resistance in B-cell malignancies. Key Findings: The overall response rate (ORR) and complete response (CR) rate were 91.5% and 85.1%, respectively for all patients Among the 43 LBCL pts, ORR and CR were 90.7% and 86.0%, respectively With a median follow-up of 45.5 months (range, 3.1–62.8), the median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were not reached KM estimates of 48-m PFS rate are 52.5% for all patients and 53.4% for LBCL patients, respectively KM estimates of 48-m OS rate are 65.4% for all patients and 66.7% for LBCL patients, respectively Safety Highlights: CRS of any grade: 93.8% | Grade ≥3: 2.1% ICANS of any grade: 6.3% | No severe cases (Grade ≥3) reported No new safety signals were observed with longer follow-up C-CAR039 has continued to show an excellent safety profile and deep and durable responses in R/R B-NHL patients, especially in those with R/R LBCL. These results continue to provide strong support for the curative potential of C-CAR039 as a next-generation therapy for R/R B-NHL. Late-stage clinical development is ongoing. "The long-term clinical outcomes data for C-CAR039 are highly encouraging, demonstrating sustained responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma," said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. "These results underscore our commitment and corporate goal to develop transformative therapies that address significant unmet medical needs in cancer." Dr. Yihong Yao, Chief Scientific Officer of AbelZeta, commented, "The strong clinical results of C-CAR039 demonstrate the added value of targeting CD20 in addition to CD19 in aggressive B-NHL. By addressing the limitations of single-antigen therapies - such as CD19 antigen escape - C-CAR039 enables deeper tissue penetration and more complete B-cell depletion. The durable responses observed support the continued advancement of C-CAR039 as a promising new treatment for patients with aggressive B-cell malignancies." For more information on the study and access to the poster presentation, please visit the EHA Library poster here. AbelZeta previously presented 30-month Phase 1 clinical trial results at the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, through oral presentation #1025, as well as at EHA 2024, through poster presentation #P1475. The data with 30 months follow up was published in Blood 2025 Apr 3;145(14):1526-1535. AbelZeta Inc. (formerly known as Cellular Biomedicine Group, Inc.), entered into a worldwide collaboration and licensing agreement with Johnson & Johnson* in 2023 to develop and commercialize next-generation CAR-T cell therapies (excluding Greater China). The Phase 1 study for C-CAR039 was conducted by AbelZeta in China for the treatment of patients with B-cell non-Hodgkin lymphoma. Johnson & Johnson is evaluating the safety and efficacy of this asset (known as JNJ-90014496 outside of Greater China) through a separate study involving a global patient population. Phase 1b data for JNJ-90014496 were presented at EHA 2025 on Friday, June 13, informing the recommended Phase 2 dose and an initial assessment of safety, efficacy and pharmacokinetics in R/R LBCL patients. For more information, please visit Johnson and Johnson website: *The legal entity to the worldwide collaboration and license agreement is Janssen Biotech, Inc., a Johnson & Johnson company. About AbelZeta Pharma, is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T therapies. Forward-Looking StatementsStatements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. Company Contact:Sarah KellyDirector of CommunicationsAbelZeta Pharma, Inc.+1 (240) 552 View original content to download multimedia: SOURCE AbelZeta Pharma, Inc.
